Tumour expression and genetic alterations of the CDR proteins, particularly CDR2L, is thought to trigger an immune response which targets both the cancer cells and the Purkinje neurons endogenously expressing the CDR proteins [19]. The gene discussed is CDR2L; the disease is cancer.